أعرض في EDS

Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial

التفاصيل البيبلوغرافية
العنوان: Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial
المؤلفون: Fatma Oral, Gözde Kübra Yardımcı, Emre Bilgin, Ertugrul Cagri Bolek, Levent Kilic
المصدر: Rheumatology. 58:925-925
بيانات النشر: Oxford University Press (OUP), 2019.
سنة النشر: 2019
مصطلحات موضوعية: Lung Diseases, medicine.medical_specialty, Cyclophosphamide, Gastroenterology, Scleroderma, law.invention, Antibodies, Monoclonal, Murine-Derived, Intravenous cyclophosphamide, Rheumatology, Randomized controlled trial, law, Internal medicine, medicine, Humans, Pharmacology (medical), business.industry, medicine.disease, Diffuse scleroderma, Scleroderma, Diffuse, Monoclonal, Rituximab, Open label, business, medicine.drug
تدمد: 1462-0332
1462-0324
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::201f5910ccb9dab18ee5e193adc4c9c8Test
https://doi.org/10.1093/rheumatology/kez033Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....201f5910ccb9dab18ee5e193adc4c9c8
قاعدة البيانات: OpenAIRE
الوصف
تدمد:14620332
14620324